Autophagy: A new target or an old strategy for the treatment of Crohn's disease?

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 7, 2013, Pages 395-401

  Nys, Kris ^a   Agostinis, Patrizia ^a   Vermeire, Séverine ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CURCUMIN; ETANERCEPT; EVEROLIMUS; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; MERCAPTOPURINE; RAPAMYCIN; TUMOR NECROSIS FACTOR ANTIBODY;

ADAPTIVE IMMUNITY; AUTOPHAGY; COMBINATION CHEMOTHERAPY; CROHN DISEASE; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LIVER TOXICITY; LYSOSOME; NONHUMAN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT;

AUTOPHAGY; AZATHIOPRINE; CROHN DISEASE; CURCUMIN; DISEASE MANAGEMENT; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879993550     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.66     Document Type: Review

References (85)

1. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
2. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010).
3. Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
4. Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207-211 (2007).
5. Parkes, M. et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39, 830-832 (2007).
6. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
7. Henckaerts, L. et al. Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease. Inflamm. Bowel Dis. 17, 1392-1397 (2011).
8. Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. Cell 147, 728-741 (2011).
9. Choi, A. M., Ryter, S. W. & Levine, B. Autophagy in human health and disease. N. Engl. J. Med. 368, 651-662 (2013).
10. Kuballa, P., Nolte, W. M., Castoreno, A. B. & Xavier, R. J. Autophagy and the immune system. Annu. Rev. Immunol. 30, 611-646 (2012).
11. Deretic, V. Autophagy as an innate immunity paradigm: expanding the scope and repertoire of pattern recognition receptors. Curr. Opin. Immunol. 24, 21-31 (2012).
12. Orvedahl, A. et al. Autophagy protects against Sindbis virus infection of the central nervous system. Cell Host Microbe 7, 115-127 (2010).
13. Watson, R. O., Manzanillo, P. S. & Cox, J. S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150, 803-815 (2012).
14. Dupont, N. et al. Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy. Cell Host Microbe 6, 137-149 (2009).
15. Yoshikawa, Y. et al. Listeria monocytogenes ActA-mediated escape from autophagic recognition. Nat. Cell Biol. 11, 1233-1240 (2009).
16. Thurston, T. L., Wandel, M. P., von Muhlinen, N., Foeglein, A. & Randow, F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414-418 (2012).
17. Alonso, S., Pethe, K., Russell, D. G. & Purdy, G. E. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc. Natl Acad. Sci. USA 104, 6031-6036 (2007).
18. Ponpuak, M. et al. Delivery of cytosolic components by autophagic adaptor protein p62 endows autophagosomes with unique antimicrobial properties. Immunity 32, 329-341 (2010).
19. Kim, B. H. et al. A family of IFN-γ-inducible 65-kD GTPases protects against bacterial infection. Science 332, 717-721 (2011).
20. Xu, Y. et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27, 135-144 (2007).
21. Delgado, M. A., Elmaoued, R. A., Davis, A. S., Kyei, G. & Deretic, V. Toll-like receptors control autophagy. EMBO J. 27, 1110-1121 (2008).
22. Shi, C. S. & Kehrl, J. H. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. J. Biol. Chem. 283, 33175-33182 (2008).
23. de Vries, H. S. et al. Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease. PLoS ONE 4, e7818 (2009).
24. Iliev, I. D. et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336, 1314-1317 (2012).
25. Lee, H. K., Lund, J. M., Ramanathan, B., Mizushima, N. & Iwasaki, A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315, 1398-1401 (2007).
26. Rathinam, V. A., Vanaja, S. K. & Fitzgerald, K. A. Regulation of inflammasome signaling. Nat. Immunol. 13, 333-2 (2012).
27. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264-268 (2008).
28. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
29. Manjithaya, R., Anjard, C., Loomis, W. F. & Subramani, S. Unconventional secretion of Pichia pastoris Acb1 is dependent on GRASP protein, peroxisomal functions, and autophagosome formation. J. Cell Biol. 188, 537-546 (2010).
30. Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573-1577 (2011).
31. Dupont, N. et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β. EMBO J. 30, 4701-4711 (2011).
32. Shi, C. S. et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255-263 (2012).
33. Plantinga, T. S. et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 60, 1229-1235 (2011).
34. Harris, J. et al. Autophagy controls IL-1β secretion by targeting pro-IL-1β for degradation. J. Biol. Chem. 286, 9587-9597 (2011).
35. Nedjic, J., Aichinger, M., Emmerich, J., Mizushima, N. & Klein, L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature 455, 396-400 (2008).
36. McLeod, I. X., Jia, W. & He, Y. W. The contribution of autophagy to lymphocyte survival and homeostasis. Immunol. Rev. 249, 195-204 (2012).
37. Strisciuglio, C. et al. Impaired autophagy leads to abnormal dendritic cell-epithelial cell interactions. J. Crohns Colitis http://dx.doi.org/10.1016/ j.crohns.2012.08.009.
38. Wildenberg, M. E. et al. Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse. Gastroenterology 142, 1493-1503 (2012).
39. Connor, A. M., Mahomed, N., Gandhi, R., Keystone, E. C. & Berger, S. A. TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. Arthritis Res. Ther. 14, R62 (2012).
40. Keller, C. W. et al. TNF-α induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J. Biol. Chem. 286, 3970-3980 (2011).
41. Jia, G., Cheng, G., Gangahar, D. M. & Agrawal, D. K. Insulin-like growth factor-1 and TNF-α regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. Immunol. Cell Biol. 84, 448-454 (2006).
42. Harris, J. & Keane, J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161, 1-9 (2010).
43. Castillo, E. F. et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc. Natl Acad. Sci. USA 109, E3168-E3176 (2012).
44. Saito, M. et al. Intestinal epithelial cells with impaired autophagy lose their adhesive capacity in the presence of TNF-α. Dig. Dis. Sci. 57, 2022-2030 (2012).
45. Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003).
46. Wildenberg, M. et al. ATG16L1 genotype is associated with response to anti-TNF in vitro [abstract P668]. J. Crohns Colitis 7 (Suppl. 1), S279 (2013).
47. Guijarro, L. G., Roman, I. D., Fernandez-Moreno, D., Gisbert, J. P. & Hernandez-Breijo, B. Is the autophagy induced by thiopurines beneficial or deleterious? Curr. Drug Metab. 13, 1267-1276 (2012).
48. Petit, E. et al. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. in Vitro 22, 632-642 (2008).
49. Kroemer, G., Marino, G. & Levine, B. Autophagy and the integrated stress response. Mol. Cell 40, 280-293 (2010).
50. Zhou, S. et al. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde? Cancer Lett. 323, 115-127 (2012).
51. Hilsden, R. J., Verhoef, M. J., Rasmussen, H., Porcino, A. & deBruyn, J. C. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm. Bowel Dis. 17, 655-662 (2011).
52. Ali, T., Shakir, F. & Morton, J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion 85, 249-255 (2012).
53. Ramsewak, R. S., DeWitt, D. L. & Nair, M. G. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine 7, 303-308 (2000).
54. Ruby, A. J., Kuttan, G., Babu, K. D., Rajasekharan, K. N. & Kuttan, R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 94, 79-83 (1995).
55. Aggarwal, B. B. & Harikumar, K. B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 41, 40-59 (2009).
56. Negi, P. S., Jayaprakasha, G. K., Jagan Mohan, R. L. & Sakariah, K. K. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J. Agric. Food Chem. 47, 4297-4300 (1999).
57. Yadav, V. R., Suresh, S., Devi, K. & Yadav, S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech 10, 752-762 (2009).
58. Han, J. et al. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 8, 812-825 (2012).
59. Alavez, S., Vantipalli, M. C., Zucker, D. J., Klang, I. M. & Lithgow, G. J. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 472, 226-229 (2011).
60. Totino, P. R., Daniel-Ribeiro, C. T., Corte-Real, S. & de Fatima Ferreira-da-Cruz, M. Plasmodium falciparum: erythrocytic stages die by autophagic-like cell death under drug pressure. Exp. Parasitol. 118, 478-486 (2008).
61. Solomon, V. R. & Lee, H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 625, 220-233 (2009).
62. Ferrer, I. R., Araki, K. & Ford, M. L. Paradoxical aspects of rapamycin immunobiology in transplantation. Am. J. Transplant. 11, 654-659 (2011).
63. Louis, E. & Belaiche, J. Hydroxychloroquine (Plaquenil) for recurrence prevention of Crohn's disease after curative surgery. Gastroenterol. Clin. Biol. 19, 233-234 (1995).
64. Glinsky, G. V. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. Cell Cycle 7, 3564-3576 (2008).
65. Massey, D. C., Bredin, F. & Parkes, M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57, 1294-1296 (2008).
66. Yang, K. & Chi, H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin. Immunol. 24, 421-428 (2013).
67. Nakagawa, S., Nishihara, K., Inui, K. & Masuda, S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur. J. Pharmacol. 696, 143-154 (2012).
68. Bruyn, G. A. et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann. Rheum. Dis. 67, 1090-1095 (2008).
69. Reinisch, W. et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am. J. Gastroenterol. 103, 2284-2292 (2008).
70. Garcia-Maurino, S., Alcaide, A. & Dominguez, C. Pharmacological control of autophagy: therapeutic perspectives in inflammatory bowel disease and colorectal cancer. Curr. Pharm. Des. 18, 3853-3873 (2012).
71. Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259-263 (2008).
72. Vermeire, S. Towards a novel molecular classification of IBD. Dig. Dis. 30, 425-427 (2012).
73. Dubinsky, M. C. et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100, 2239-2247 (2005).
74. Rutgeerts, P., Vermeire, S. & Van, A. G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136, 1182-1197 (2009).
75. Li, F., Wang, L., Burgess, R. J. & Weinshilboum, R. M. Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet. Genomics 18, 1083-1094 (2008).
76. Weersma, R. K. & Wijmenga, C. Using genetic information for the identification, classification and treatment of Crohn's disease: are we there yet? Expert. Rev. Gastroenterol. Hepatol. 2, 719-721 (2008).
77. Cuffari, C. The genetics of inflammatory bowel disease: diagnostic and therapeutic implications. World J. Pediatr. 6, 203-209 (2010).
78. Vermeire, S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 24 (Suppl. 3), 2-10 (2006).
79. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
80. White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401-410 (2012).
81. De Cassan, C., Fiorino, G. & Danese, S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? Dig. Dis. 30, 368-375 (2012).
82. Baert, F. et al. Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59, 304-314 (2004).
83. Van Assche, G., Vermeire, S. & Rutgeerts, P. The potential for disease modification in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 7, 79-85 (2010).
84. Magro, F. & Portela, F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 24 (Suppl. 1), 3-14 (2010).
85. Perrier, C. & Rutgeerts, P. New drug therapies on the horizon for IBD. Dig. Dis. 30 (Suppl. 1), 100-105 (2012).